-
Je něco špatně v tomto záznamu ?
Novel C-2 Aromatic Heterocycle-Substituted Triterpenoids Inhibit Hedgehog Signaling in GLI1 Overexpression Cancer Cells
I. Frydrych, B. Choma, L. Slavíková, J. Pokorný, N. Jakubcová, S. Ludha, S. Gurská, J. Řehulka, B. Lišková, P. Džubák, M. Hajdúch, M. Urban
Status neindexováno Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2016
PubMed Central
od 2016
Europe PubMed Central
od 2016
ROAD: Directory of Open Access Scholarly Resources
od 2016
PubMed
40124057
DOI
10.1021/acsomega.4c11479
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
The hedgehog signaling pathway plays an important role in vertebrate embryonic development, tissue homeostasis, and tumorigenesis. Constitutive activation of Hh signaling in various human tumors leads to GLI-mediated transcription and tumor progression. Based on the preliminary screening of a large library of known triterpenes that exhibited interesting Hh inhibitory activity, we designed and synthesized a new series of triterpenoid analogues containing aromatic heterocyclic substituents at position C-2 to enhance their interference with Hh signaling. In this study, we evaluated the effect of 15 synthesized triterpenoids on cell proliferation and Hh pathway activity in relevant cancer cell lines. Among these compounds, two derivatives, 11a and 11b, both featuring a furan ring at position C-2, demonstrated potent inhibitory effects on proliferation and induced cell death in nonsmall cell lung cancer (NSCLC) and prostate cancer cell lines exhibiting hyper-activated Hh signaling. Moreover, these compounds significantly reduced GLI-mediated transcription in cell-based reporter assays. Detailed immunoblot analyses revealed that compounds 11a and 11b decreased the expression of endogenous GLI1 protein and its target genes associated with tumor progression and proliferation, such as Cyclin D1, N-Myc, and Bcl-2, in A549 and DU-145 cancer cells. These findings suggest that the antiproliferative effects of 11a and 11b are mediated through inhibition of the Hh signaling pathway and are promising candidates for the development of new anticancer therapies targeting Hh-dependent tumors.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25008209
- 003
- CZ-PrNML
- 005
- 20250422095758.0
- 007
- ta
- 008
- 250408s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acsomega.4c11479 $2 doi
- 035 __
- $a (PubMed)40124057
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Frydrych, Ivo $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic $1 https://orcid.org/0000000314121607 $7 xx0169396
- 245 10
- $a Novel C-2 Aromatic Heterocycle-Substituted Triterpenoids Inhibit Hedgehog Signaling in GLI1 Overexpression Cancer Cells / $c I. Frydrych, B. Choma, L. Slavíková, J. Pokorný, N. Jakubcová, S. Ludha, S. Gurská, J. Řehulka, B. Lišková, P. Džubák, M. Hajdúch, M. Urban
- 520 9_
- $a The hedgehog signaling pathway plays an important role in vertebrate embryonic development, tissue homeostasis, and tumorigenesis. Constitutive activation of Hh signaling in various human tumors leads to GLI-mediated transcription and tumor progression. Based on the preliminary screening of a large library of known triterpenes that exhibited interesting Hh inhibitory activity, we designed and synthesized a new series of triterpenoid analogues containing aromatic heterocyclic substituents at position C-2 to enhance their interference with Hh signaling. In this study, we evaluated the effect of 15 synthesized triterpenoids on cell proliferation and Hh pathway activity in relevant cancer cell lines. Among these compounds, two derivatives, 11a and 11b, both featuring a furan ring at position C-2, demonstrated potent inhibitory effects on proliferation and induced cell death in nonsmall cell lung cancer (NSCLC) and prostate cancer cell lines exhibiting hyper-activated Hh signaling. Moreover, these compounds significantly reduced GLI-mediated transcription in cell-based reporter assays. Detailed immunoblot analyses revealed that compounds 11a and 11b decreased the expression of endogenous GLI1 protein and its target genes associated with tumor progression and proliferation, such as Cyclin D1, N-Myc, and Bcl-2, in A549 and DU-145 cancer cells. These findings suggest that the antiproliferative effects of 11a and 11b are mediated through inhibition of the Hh signaling pathway and are promising candidates for the development of new anticancer therapies targeting Hh-dependent tumors.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Choma, Barbora $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, Olomouc 771 46, Czech Republic
- 700 1_
- $a Slavíková, Lucie $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, Olomouc 771 46, Czech Republic
- 700 1_
- $a Pokorný, Jan $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, Olomouc 771 46, Czech Republic $u Laboratory of Medicinal and Organic Chemistry, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic
- 700 1_
- $a Jakubcová, Nikola $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, Olomouc 771 46, Czech Republic $u Laboratory of Medicinal and Organic Chemistry, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic
- 700 1_
- $a Ludha, Sandra $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, Olomouc 771 46, Czech Republic
- 700 1_
- $a Gurská, Soňa $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic
- 700 1_
- $a Řehulka, Jiří $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic
- 700 1_
- $a Lišková, Barbora $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic
- 700 1_
- $a Džubák, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Czech Advanced Technology and Research Institute, Palacký University Olomouc, Šlechtitelů 241/27, Olomouc-Holice 783 71, Czech Republic
- 700 1_
- $a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc and University Hospital Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Czech Advanced Technology and Research Institute, Palacký University Olomouc, Šlechtitelů 241/27, Olomouc-Holice 783 71, Czech Republic
- 700 1_
- $a Urban, Milan $u Department of Organic Chemistry, Faculty of Science, Palacký University Olomouc, 17. listopadu 1192/12, Olomouc 771 46, Czech Republic $u Laboratory of Medicinal and Organic Chemistry, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Hněvotínská 1333/5, Olomouc 779 00, Czech Republic $1 https://orcid.org/000000028249028X $7 xx0117688
- 773 0_
- $w MED00207589 $t ACS omega $x 2470-1343 $g Roč. 10, č. 10 (2025), s. 10617-10632
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40124057 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250408 $b ABA008
- 991 __
- $a 20250422095759 $b ABA008
- 999 __
- $a ok $b bmc $g 2306304 $s 1245284
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2025 $b 10 $c 10 $d 10617-10632 $e 20250304 $i 2470-1343 $m ACS omega $n ACS Omega $x MED00207589
- LZP __
- $a Pubmed-20250408